XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 4 - Inventory | 3 Months Ended
--- | ---
Mar. 31, 2025
Notes to Financial Statements |
Inventory Disclosure [Text Block] | NOTE 4 - INVENTORY The following table presents our inventory as of March 31, 2025 and December 31, 2024 (in thousands):
​ |  | March 31, 2025 |  |  | December 31, 2024 |
Raw Materials |  | $ | 4,119 |  |  | $ | 28,151 |
Work in Process |  |  | 142,923 |  |  |  | 68,369 |
Finished Goods |  |  | 10,717 |  |  |  | 13,938 |
Total Inventory |  | $ | 157,759 |  |  | $ | 110,458 |
Inventory is stated at the lower of cost or net realizable value and consists of raw materials, work-in-process and finished goods. Cost is determined using a standard cost method, which approximates actual cost, and assumes a FIFO flow of goods. Inventory that is used for clinical development purposes is expensed to research and development expense when consumed. At March 31, 2025, all our inventory was solely related to BRIUMVI, which was approved by the FDA on December 28, 2022, at which time we began to capitalize costs to manufacture BRIUMVI. Prior to the FDA approval of BRIUMVI, all costs related to the manufacturing of BRIUMVI and related material were charged to research and development expense in the period incurred. The work in process materials consist primarily of bulk drug substance, which has a multi-year shelf life. When the bulk drug substance is manufactured into BRIUMVI finished goods, those finished goods have a shelf life of three years from the date of manufacture. Our expectation is to sell finished goods at least twelve months prior to expiration. Due to our long manufacturing lead time, it was necessary to build inventory levels to support BRIUMVI forecasted sales, to ensure appropriate safety stock levels, and meet our commitment to supply BRIUMVI to Neuraxpharm related to the Commercialization Agreement. As a result of being in the early stages of the BRIUMVI product launch, the Company is continuing to evaluate the length of its operating cycle. On a quarterly basis, the Company analyzes our inventory levels for excess quantities and obsolescence (expiration), taking into account factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf-life. At March 31, 2025, we determined that a reserve related to BRIUMVI inventory for excess quantities and obsolescence is not required. In addition, since FDA approval of BRIUMVI, the Company has not recorded any inventory write downs. The United States and other countries have recently imposed, and may continue to impose, new tariffs. Tariffs are an inventoriable cost, and our sole supplier of bulk drug substance is located outside of the U.S. While the tariffs imposed to date have not resulted in a material impact on our business and the results of operations, we continue to evaluate their impact on our business and results of operations.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration